SequelSEC

Vera Therapeutics, Inc. VERA

Pharmaceutical Preparations · CIK 0001831828 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$315.47M
Fiscal year ended 2025-12-31
Free cash flow
-$241.73M
Fiscal year ended 2025-12-31

Vera Therapeutics, Inc. (VERA) reported net income of -$299.62M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Vera Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Vera Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$315.47M-$167.17M-$102.01M-$90.90M-$34.40M-$52.24M
Net income-$299.62M-$152.15M-$95.99M-$89.06M-$32.61M-$53.41M
Research & development$215.26M$126.17M$78.22M$68.99M$22.48M$45.21M
Weighted-average diluted sharesshares 64.23Mshares 55.33Mshares 42.71Mshares 26.57Mshares 13.44MUnavailable
Pretax income-$299.61M-$152.15M-$95.99M-$89.06M-$32.61M-$53.41M
Income tax expense$1.00K$1.00K$1.00K$1.00K$1.00K-$1.00K
Diluted EPS$-4.66$-2.75$-2.25$-3.35$-2.43Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$100.22M$41.00M$23.79M$21.91M$11.92M$4.04M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Vera Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$354.72M$92.65M$45.68M$43.46M$79.67M$53.65M
Total assets$734.73M$655.68M$175.55M$131.44M$83.75M$54.55M
Current assets$728.88M$651.22M$172.02M$125.70M$82.54M$54.26M
Total liabilities$130.21M$78.53M$73.86M$54.53M$14.16M$4.33M
Current liabilities$53.46M$25.37M$22.30M$25.60M$7.69M$2.41M
Total equity incl. NCI$604.52M$577.16M$101.68M$76.91M$69.59M-$89.35M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$139.58M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$74.84M$50.69M$49.88M$24.81M$4.92M$0
Accounts payable$21.90M$7.66M$11.12M$11.99M$1.38M$909.00K

Cash flow

Vera Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$241.10M-$134.68M-$92.18M-$67.60M-$23.71M-$34.81M
Capital expenditures$630.00K$972.00K$63.00K$62.00K$0$99.00K
Investing cash flow$194.29M-$425.03M-$39.43M-$70.55M-$4.20M-$42.00K
Financing cash flow$308.90M$606.67M$133.54M$101.93M$53.88M$85.29M
Net change in cash$262.08M$46.96M$1.93M-$36.22M$25.97M$50.44M
Stock-based compensation$37.93M$20.80M$11.49M$8.89M$3.01M$331.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$13.00K$0UnavailableUnavailableUnavailable
Depreciation & amortization$468.00K$105.00K$21.00K-$846.00K$176.00K$251.00K

Derived

Vera Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$241.73M-$135.65M-$92.24M-$67.66M-$23.71M-$34.91M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio13.64x25.67x7.71x4.91x10.73x22.55x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.12xUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VERA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.